Phase II trial of irinotecan, S-1, and bevacizumab (IRIS/Bev) combination chemotherapy as second line for advanced colorectal cancer (NCCSG04).
Yasumasa Takii
No relevant relationships to disclose
Kouichi Hurukawa
No relevant relationships to disclose
Satoshi Maruyama
No relevant relationships to disclose
Toshiyuki Yamazaki
No relevant relationships to disclose
Jun Nishimura
No relevant relationships to disclose
Mikako Kawahara
No relevant relationships to disclose
Takemi Tomiyama
No relevant relationships to disclose
Kohei Akazawa
No relevant relationships to disclose
Katsuyoshi Hatakeyama
No relevant relationships to disclose